CMS has finally released its plan for market-based reimbursement of lab testing, and early reaction from industry seems to be that large test providers such as Quest and LabCorp will benefit most from the new system.
During a recent panel discussion regarding the regulation of laboratory-developed tests (LDTs), Elizabeth Mansfield, Deputy Director for Personalized Medicine at FDA, announced that FDA will be increasingly focused on what she called "complementary diagnostics."
Making the maximum use of discoveries that have already been made is a central interest of mine, and a couple of recent articles have described novel ways that targeted therapies might be "discovered" for individual patients.
An FDA official recently stated that the final version of the draft guidance regarding regulation of laboratory-developed tests (LDTs) is not likely to be released before the end of this year.
A fascinating article was just published by Ariana Cha in the Washington Post describing how IBM's Watson is being used at 14 major cancer centers to help interpret genomic data.